

**Huntington's Disease Society  
of America, Inc.  
and Affiliates**

**Consolidated Financial Statements  
and Supplemental Material**  
Year Ended September 30, 2009

**Huntington's Disease Society  
of America, Inc.  
and Affiliates**

**Consolidated Financial Statements  
and Supplemental Material**  
Year Ended September 30, 2009

# Huntington's Disease Society of America, Inc. and Affiliates

## Contents

|  |      |
|--|------|
| <b>Independent auditors' report</b>                          | 3    |
| <b>Consolidated financial statements:</b>                    |      |
| Statement of financial position                              | 4    |
| Statement of activities                                      | 5    |
| Statement of functional expenses                             | 6    |
| Statement of cash flows                                      | 7    |
| Notes to consolidated financial statements                   | 8-23 |
| <b>Independent auditors' report on supplemental material</b> | 24   |
| <b>Supplemental material:</b>                                |      |
| Consolidating statement of financial position                | 25   |
| Consolidating statement of activities                        | 26   |

## Independent Auditors' Report

To the Board of Trustees  
Huntington's Disease Society  
of America, Inc. and Affiliates  
New York, New York

We have audited the accompanying consolidated statement of financial position of Huntington's Disease Society of America, Inc. and Affiliates (collectively the "Society") as of September 30, 2009, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Society's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. Information for the year ended September 30, 2008 is presented for comparative purposes only and was extracted from the consolidated financial statements of the Society for that year, on which we expressed an unqualified opinion on those statements dated April 15, 2009.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Huntington's Disease Society of America, Inc. and Affiliates as of September 30, 2009, and the changes in their net assets and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

*BDO Seidman, LLP*

March 31, 2010

# Huntington's Disease Society of America, Inc. and Affiliates

## Consolidated Statement of Financial Position (with comparative totals for 2008)

| <i>September 30,</i>                            | <b>2009</b>        | <b>2008</b> |
|---|--------------------|-------------|
| <b>Assets</b>                                   |                    |             |
| Cash and cash equivalents (Note 2(d))           | <b>\$3,002,276</b> | \$2,540,239 |
| Investments, at fair value (Notes 2(m) and 3)   | <b>806,979</b>     | 793,450     |
| Contributions receivable                        | <b>1,072,882</b>   | 351,054     |
| Pledges receivable, net (Notes 2(j) and 4)      | <b>166,320</b>     | 893,410     |
| Prepaid expenses and deposits                   | <b>148,199</b>     | 139,387     |
| Cash surrender value of life insurance (Note 5) | <b>110,838</b>     | 104,032     |
| Fixed assets, net (Notes 2(e) and 6)            | <b>18,077</b>      | 33,577      |
|   | <b>\$5,325,571</b> | \$4,855,149 |
| <b>Liabilities and Net Assets</b>               |                    |             |
| <b>Liabilities:</b>                             |                    |             |
| Accounts payable and accrued expenses           | <b>\$ 544,949</b>  | \$ 521,661  |
| Accrued compensation                            | <b>274,789</b>     | 195,628     |
| Research grants payable                         | <b>2,507,500</b>   | 2,417,500   |
| Accrued lease commitment (Note 7)               | <b>113,314</b>     | 111,408     |
| Deferred revenue                                | <b>115,478</b>     | 82,521      |
| <b>Total liabilities</b>                        | <b>3,556,030</b>   | 3,328,718   |
| <b>Commitments (Notes 2, 7 and 13)</b>          |                    |             |
| <b>Net assets (Notes 2(c), 9, 10 and 11):</b>   |                    |             |
| Unrestricted                                    | <b>41,002</b>      | (32,393)    |
| Unrestricted – Board designated                 | <b>443,603</b>     | 443,603     |
| Temporarily restricted                          | <b>732,736</b>     | 550,259     |
| Permanently restricted                          | <b>552,200</b>     | 564,962     |
| <b>Total net assets</b>                         | <b>1,769,541</b>   | 1,526,431   |
|   | <b>\$5,325,571</b> | \$4,855,149 |

*See accompanying notes to consolidated financial statements.*

# Huntington's Disease Society of America, Inc. and Affiliates

## Consolidated Statement of Activities (with comparative totals for 2008)

Year ended September 30,

|  | Unrestricted       |                   | Temporarily<br>restricted | Permanently<br>restricted | 2009                | 2008                |
|--|--------------------|-------------------|---------------------------|---------------------------|---------------------|---------------------|
|  | Current            | Board designated  |                           |                           |                     |                     |
| <b>Public support and revenue:</b>                                   |                    |                   |                           |                           |                     |                     |
| Public donations (Note 2(i))   | \$ 2,433,231       | \$ -              | \$ 297,000                | \$ -                      | \$ 2,730,231        | \$ 3,881,317        |
| Foundation grants and corporate contributions (Notes 2(i) and 8)     | 2,333,317          | -                 | 951,063                   | -                         | 3,284,380           | 2,134,837           |
| Federal campaign   | 299,787            | -                 | -                         | -                         | 299,787             | 304,057             |
| Investment income  | 47,727             | -                 | 12,923                    | 27,136                    | 87,786              | 48,361              |
| Sale of materials  | 49,772             | -                 | -                         | -                         | 49,772              | 136,241             |
| Donated services (Note 12)   | 90,069             | -                 | -                         | -                         | 90,069              | 59,690              |
| Other  | 1,044              | -                 | -                         | -                         | 1,044               | 24,416              |
| Net assets released from restrictions (Note 9)                       | 1,226,281          | -                 | (1,186,383)               | (39,898)                  | -                   | -                   |
| <b>Total public support and revenue</b>                              | <b>6,481,228</b>   | <b>-</b>          | <b>74,603</b>             | <b>(12,762)</b>           | <b>6,543,069</b>    | <b>6,588,919</b>    |
| <b>Expenses:</b>   |                    |                   |                           |                           |                     |                     |
| Program services:  |                    |                   |                           |                           |                     |                     |
| Research   | 2,017,682          | -                 | -                         | -                         | 2,017,682           | 2,350,960           |
| Family services  | 2,124,771          | -                 | -                         | -                         | 2,124,771           | 1,934,209           |
| Education  | 835,254            | -                 | -                         | -                         | 835,254             | 635,287             |
| Chapter development  | 1,650,770          | -                 | -                         | -                         | 1,650,770           | 1,433,474           |
| <b>Total program services</b>  | <b>6,628,477</b>   | <b>-</b>          | <b>-</b>                  | <b>-</b>                  | <b>6,628,477</b>    | <b>6,353,930</b>    |
| Supporting services:   |                    |                   |                           |                           |                     |                     |
| Management and general   | 948,373            | -                 | -                         | -                         | 948,373             | 1,080,446           |
| Fundraising  | 1,141,438          | -                 | -                         | -                         | 1,141,438           | 1,051,704           |
| <b>Total supporting services</b>                                     | <b>2,089,811</b>   | <b>-</b>          | <b>-</b>                  | <b>-</b>                  | <b>2,089,811</b>    | <b>2,132,150</b>    |
| <b>Total expenses</b>  | <b>8,718,288</b>   | <b>-</b>          | <b>-</b>                  | <b>-</b>                  | <b>8,718,288</b>    | <b>8,486,080</b>    |
| <b>Net income (loss) from operations before nonoperating revenue</b> | <b>(2,237,060)</b> | <b>-</b>          | <b>74,603</b>             | <b>(12,762)</b>           | <b>(2,175,219)</b>  | <b>(1,897,161)</b>  |
| <b>Nonoperating revenue:</b>   |                    |                   |                           |                           |                     |                     |
| Special events:  |                    |                   |                           |                           |                     |                     |
| Gross receipts   | 3,953,255          | -                 | 107,874                   | -                         | 4,061,129           | 3,959,924           |
| Less: Direct costs   | (1,642,800)        | -                 | -                         | -                         | (1,642,800)         | (2,051,682)         |
| <b>Net revenue from special events</b>                               | <b>2,310,455</b>   | <b>-</b>          | <b>107,874</b>            | <b>-</b>                  | <b>2,418,329</b>    | <b>1,908,242</b>    |
| <b>Change in net assets</b>  | <b>73,395</b>      | <b>-</b>          | <b>182,477</b>            | <b>(12,762)</b>           | <b>243,110</b>      | <b>11,081</b>       |
| <b>Net assets, beginning of year</b>                                 | <b>(32,393)</b>    | <b>443,603</b>    | <b>550,259</b>            | <b>564,962</b>            | <b>1,526,431</b>    | <b>1,515,350</b>    |
| <b>Net assets, end of year</b>                                       | <b>\$ 41,002</b>   | <b>\$ 443,603</b> | <b>\$ 732,736</b>         | <b>\$552,200</b>          | <b>\$ 1,769,541</b> | <b>\$ 1,526,431</b> |

*See accompanying notes to consolidated financial statements.*

# Huntington's Disease Society of America, Inc. and Affiliates

## Consolidated Statement of Functional Expenses (with comparative totals for 2008)

Year ended September 30,

|  | Program services   |                    |                  |                     |                        | Supporting services    |                    |                           | 2009               | 2008               |
|--|--------------------|--------------------|------------------|---------------------|------------------------|------------------------|--------------------|---------------------------|--------------------|--------------------|
|  | Research           | Family services    | Education        | Chapter development | Total program services | Management and general | Fundraising        | Total supporting services |                    |                    |
| <b>Salaries and related expenses:</b>                      |                    |                    |                  |                     |                        |                        |                    |                           |                    |                    |
| Salaries   | \$ 302,276         | \$ 395,341         | \$ 92,075        | \$ 676,605          | \$1,466,297            | \$354,527              | \$ 381,266         | \$ 735,793                | <b>\$2,202,090</b> | \$2,043,384        |
| Payroll taxes and employee benefits (Note 12)              | 101,793            | 133,134            | 29,482           | 223,091             | 487,500                | 118,510                | 134,831            | 253,341                   | <b>740,841</b>     | 648,143            |
| <b>Total salaries and related expenses</b>                 | <b>404,069</b>     | <b>528,475</b>     | <b>121,557</b>   | <b>899,696</b>      | <b>1,953,797</b>       | <b>473,037</b>         | <b>516,097</b>     | <b>989,134</b>            | <b>2,942,931</b>   | <b>2,691,527</b>   |
| <b>Other expenses:</b>                                     |                    |                    |                  |                     |                        |                        |                    |                           |                    |                    |
| Office supplies  | 7,655              | 17,041             | 14,904           | 31,890              | 71,490                 | 26,848                 | 14,495             | 41,343                    | <b>112,833</b>     | 117,342            |
| Telephone  | 7,723              | 13,912             | 9,316            | 82,051              | 113,002                | 13,560                 | 19,472             | 33,032                    | <b>146,034</b>     | 140,310            |
| Postage and shipping                                       | 1,430              | 8,933              | 62,743           | 48,035              | 121,141                | 70,429                 | 58,037             | 128,466                   | <b>249,607</b>     | 166,768            |
| Rent and occupancy charges (Note 7)                        | 26,752             | 26,752             | 26,794           | 105,475             | 185,773                | 26,759                 | 26,752             | 53,511                    | <b>239,284</b>     | 245,473            |
| Printing and publications                                  | 12,400             | 5,956              | 390,555          | 39,921              | 448,832                | 64,299                 | 20,014             | 84,313                    | <b>533,145</b>     | 281,644            |
| Conferences, meetings and travel                           | 106,807            | 81,095             | 31,636           | 146,572             | 366,110                | 66,304                 | 38,434             | 104,738                   | <b>470,848</b>     | 290,736            |
| Insurance  | 1,398              | 4,894              | 6,293            | 11,617              | 24,202                 | 5,593                  | 6,293              | 11,886                    | <b>36,088</b>      | 40,374             |
| Prizes, gifts and products sold                            | 166                | 342                | 6,725            | 15,615              | 22,848                 | 9,591                  | 163,741            | 173,332                   | <b>196,180</b>     | 59,170             |
| Professional services                                      | 48,281             | 384,288            | 98,194           | 164,142             | 694,905                | 61,067                 | 108,529            | 169,596                   | <b>864,501</b>     | 868,978            |
| Research grants and other awards                           | 1,295,166          | 1,009,662          | -                | -                   | 2,304,828              | -                      | -                  | -                         | <b>2,304,828</b>   | 3,186,085          |
| Equipment rental   | 7,286              | 7,286              | 7,285            | 15,125              | 36,982                 | 8,899                  | 8,549              | 17,448                    | <b>54,430</b>      | 54,319             |
| Donated services and materials (Note 11)                   | 90,069             | -                  | -                | -                   | 90,069                 | -                      | -                  | -                         | <b>90,069</b>      | 59,690             |
| Bad debt expense   | 8,211              | 28,737             | 36,948           | 61,580              | 135,476                | 32,843                 | 36,948             | 69,791                    | <b>205,267</b>     | 15,240             |
| Other  | 269                | 7,398              | 22,304           | 24,960              | 54,931                 | 75,125                 | 124,077            | 199,202                   | <b>254,133</b>     | 247,805            |
| <b>Total expenses before depreciation and amortization</b> | <b>2,017,682</b>   | <b>2,124,771</b>   | <b>835,254</b>   | <b>1,646,679</b>    | <b>6,624,386</b>       | <b>934,354</b>         | <b>1,141,438</b>   | <b>2,075,792</b>          | <b>8,709,178</b>   | <b>8,465,461</b>   |
| <b>Depreciation and amortization</b>                       | <b>-</b>           | <b>-</b>           | <b>-</b>         | <b>4,091</b>        | <b>4,091</b>           | <b>14,019</b>          | <b>-</b>           | <b>14,019</b>             | <b>18,110</b>      | <b>20,619</b>      |
|  | <b>\$2,017,682</b> | <b>\$2,124,771</b> | <b>\$835,254</b> | <b>\$1,650,770</b>  | <b>\$6,628,477</b>     | <b>\$948,373</b>       | <b>\$1,141,438</b> | <b>\$2,089,811</b>        | <b>\$8,718,288</b> | <b>\$8,486,080</b> |

*See accompanying notes to consolidated financial statements.*

# Huntington's Disease Society of America, Inc. and Affiliates

## Consolidated Statement of Cash Flows (with comparative totals for 2008)

| <i>Year ended September 30,</i>   | 2009               | 2008               |
|---|--------------------|--------------------|
| <b>Cash flows from operating activities:</b>  |                    |                    |
| Change in net assets  | \$ 243,110         | \$ 11,081          |
| Adjustments to reconcile change in net assets to net cash provided by operating activities: |                    |                    |
| Depreciation and amortization   | 18,110             | 20,619             |
| Provisions for bad debt   | 205,267            | 15,240             |
| Realized loss on investments  | -                  | 3,858              |
| Unrealized (gain) loss on investments   | (21,762)           | 613                |
| Donated investments   | (152,745)          | (95,027)           |
| Changes in assets and liabilities:  |                    |                    |
| (Increase) decrease in:   |                    |                    |
| Contributions receivable  | (721,828)          | 380,118            |
| Pledges receivable  | 521,823            | (343,457)          |
| Prepaid expenses and deposits   | (8,812)            | (65,979)           |
| Cash surrender value of life insurance  | (6,806)            | (5,369)            |
| Increase (decrease) in:   |                    |                    |
| Accounts payable and accrued expenses   | 23,288             | (63,905)           |
| Accrued salaries and related liabilities  | 79,161             | 36,203             |
| Research grants payable   | 90,000             | 1,084,000          |
| Accrued lease commitment  | 1,906              | 11,008             |
| Deferred revenue  | 32,957             | 9,196              |
| <b>Net cash provided by operating activities</b>  | <b>303,669</b>     | <b>998,199</b>     |
| <b>Cash flows from investing activities:</b>  |                    |                    |
| Purchase of fixed assets  | (2,610)            | (6,649)            |
| Purchase of investments   | (320,573)          | (938,488)          |
| Proceeds from sale of investments   | 481,551            | 536,568            |
| <b>Net cash provided by (used in) investing activities</b>                                  | <b>158,368</b>     | <b>(408,569)</b>   |
| <b>Net increase in cash and cash equivalents</b>  | <b>462,037</b>     | <b>589,630</b>     |
| <b>Cash and cash equivalents, beginning of year</b>   | <b>2,540,239</b>   | <b>1,950,609</b>   |
| <b>Cash and cash equivalents, end of year</b>   | <b>\$3,002,276</b> | <b>\$2,540,239</b> |

*See accompanying notes to consolidated financial statements.*

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

- 1. Nature of Organization**

The Huntington's Disease Society of America, Inc. and Affiliates (collectively the "Society") is a national, voluntary health organization dedicated to improving the lives of people with Huntington's disease and their families.
  
- 2. Summary of Significant Accounting Policies**

  - (a) Principles of Consolidation*

The consolidated financial statements include the accounts of the Huntington's Disease Society of America, Inc. ("HDSA") and its wholly-owned supporting organizations, HDSA Research Initiatives, Inc. and HDSA Care Centers Initiatives, Inc. (the "Affiliates"). All material intercompany accounts and transactions have been eliminated in consolidation.
  
  - (b) Basis of Accounting and Presentation*

The financial statements of the Society have been prepared on the accrual basis. In the statement of financial position, assets are presented in order of liquidity or conversion to cash and liabilities are reflected in order of their maturity resulting in the use of cash.
  
  - (c) Financial Statement Presentation*

The classification of a not-for-profit organization's net assets and its support, revenue and expenses is based on the existence or absence of donor-imposed restrictions. It requires that the amounts for each of three classes of net assets, permanently restricted, temporarily restricted, and unrestricted, be displayed in a statement of financial position and that the amounts of change in each of those classes of net assets be displayed in a statement of activities.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

These classes are defined as follows:

- (i) **Permanently Restricted** - Net assets resulting from contributions and other inflows of assets whose use by the Society is limited by donor-imposed stipulations that neither expire by passage of time nor can be fulfilled or otherwise removed by actions of the Society.
- (ii) **Temporarily Restricted** - Net assets resulting from contributions and other inflows of assets whose use by the Society is limited by donor-imposed stipulations that either expire by passage of time or can be fulfilled and removed by actions of the Society pursuant to those stipulations. When such stipulations end or are fulfilled, such temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities.
- (iii) **Unrestricted** - The part of net assets that is neither permanently nor temporarily restricted by donor-imposed stipulations. They represent resources over which the Society has full discretion with respect to its use.
- (iv) **Unrestricted - Board designated** - Net assets consisting of contributions to the Society that can be spent at the discretion of the Board of Trustees of the Society.

(d) *Cash and Cash Equivalents*

The Society considers all highly liquid instruments purchased with a maturity of three months or less to be cash and cash equivalents.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

(e) *Fixed Assets*

Fixed assets are recorded at cost, net of accumulated depreciation. Depreciation of furniture and equipment is computed using the straight-line method utilizing a half-year convention over the estimated useful lives of the assets. Leasehold improvements are amortized on a straight-line method over their estimated useful life or the life of the improvement, whichever is shorter.

The estimated useful lives of the assets are as follows:

|                         |            |
|-------------------------|------------|
| Furniture and equipment | 3-7 years  |
| Leasehold improvements  | 7-10 years |

(f) *Functional Allocation of Expenses*

The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain administrative costs have been allocated among the programs and supporting services based on benefits received.

(g) *Income Taxes*

The Society is exempt from Federal income tax under Section 501(c)(3) of the Internal Revenue Code (the "Code"), and therefore has made no provision for income taxes in the accompanying financial statements. In addition, the Society has been determined by the Internal Revenue Service not to be a "private foundation" within the meaning of Section 509(a)(c) of the Code. There was no unrelated business income for the year ended September 30, 2009. The Society did not take any uncertain tax position in 2009, therefore no provision for a tax liability is necessary.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

The Affiliates operate as support organizations exempt from Federal income tax under Section 501(c)(3) of the Code and are classified as publicly supported organizations as described in Section 509(a)(3) of the Code. There was no unrelated business income for the year ended September 30, 2009.

*(h) Use of Estimates*

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

*(i) Contributions*

Contributions received are recorded as unrestricted, temporarily restricted or permanently restricted support, depending on the existence and/or nature of any donor-imposed restrictions. Contributions with purpose or time restrictions are reported as increases in temporarily restricted net assets. When a donor-imposed restriction expires, that is, when a time restriction ends or purpose restriction is fulfilled, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Restricted gifts and grants, received and utilized in the current year, are reflected in the consolidated statement of activities as unrestricted net assets.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

(j) *Promises to Give*

Unconditional promises to give are recognized as contribution revenue in the period received and as assets, decreases of liabilities, or expenses depending on the form of the benefits received and are classified as either unrestricted, temporarily restricted, or permanently restricted support. Promises to give are recorded at net realizable value if expected to be collected in one year. Unconditional promises to give that are expected to be collected in the future years are recorded at the present value of these estimated future cash flows.

(k) *Concentration of Credit Risk*

Financial instruments that potentially subject the Society to concentration of credit risk consist primarily of cash, cash equivalents, and investments. At September 30, 2009, the Society held cash deposits at financial institutions which exceeded the Federal Depository Insurance Coverage ("FDIC") limit.

(l) *Donated Services*

Donated services are valued at their fair market value. Donated services are recognized if the services received (a) create or enhance non-financial assets or (b) require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not donated.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

(m) *Investment Valuation and Income Recognition*

On October 1, 2008, the Society adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 (formerly SFAS No. 157), “Fair Value Measurements”. This statement defines fair value, establishes a framework for measuring fair value and expands the disclosures about fair value measurements. ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in a principal or most advantageous market. Fair value is a market-based measurement that is determined based on inputs, which refer broadly to assumptions that market participants use in pricing assets or liabilities. These inputs can be readily observable, market corroborated, or unobservable. ASC 820-10 established a fair value hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value in three broad levels. The standard requires that assets and liabilities be classified in their entirety based on the level of input that is significant to the fair value measurement. Assessing the significance of a particular input may require judgment considering factors specific to the asset or liability, and may affect the valuation of the asset or liability, and may affect the valuation of the asset or liability and their placement within the fair value hierarchy. The Memorial classifies fair value balances based on the fair value hierarchy defined by ASC 820-10 as follows:

Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Valuation adjustments and block discounts are not applied to Level 1 instruments.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The Society's investment in certificates of deposit represents deposits with original maturities of greater than 3 months from the date of purchase, which the Society considers to be short-term investments. The certificates of deposit represent interest-bearing cash deposits and are categorized as Level 1 of the fair value hierarchy.

The Society's holdings in mutual funds consist principally of debt and equity securities carried at their stated unit values provided by the investment managers of the funds. Each of these investment managers provides observable detailed information about the underlying securities, all of which are publicly-traded securities (equities, treasuries and bonds). The valuation of these investments is based on Level 2 inputs within the hierarchy used in measuring fair value.

Investments in common stocks and government bonds, if any, are adjusted to their fair market value at the statement of financial position date, resulting in either an unrealized gain or loss.

Investment income is recognized when earned and consists of interest and dividends. Dividends are recorded on the ex-dividend date. Purchases and sales are recorded on a trade-date basis.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

(n) *Comparative Financial Information*

The financial statements include certain prior year summarized comparative information. With respect to the statement of activities, prior year information is not presented by net asset class. With respect to the statement of functional expenses, the prior year expenses by expense classification are presented in total rather than by functional category. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the prior year financial statements from which the summarized information was derived.

(o) *Recently Issued Accounting Pronouncements*

(i) *Net Asset Classification*

In August 2009, the FASB issued ASC 958-205 (formerly FSP No. 117-1), "Endowments of Not-for-Profit Organizations: Net Asset Classification of Funds Subject to an Enacted Version of the Uniform Prudent Management of Institutional Funds Act ("UPMIFA"), and Enhanced Disclosures for All Endowment Funds". This statement is intended to improve the quality and consistency of financial reporting of endowments held by not-for-profit organizations. This statement provides guidance on classifying the net assets (equity) associated with donor-restricted endowment funds held by organizations that are subject to an enacted version of UPMIFA, which serves as a model act for states to modernize their laws governing donor-restricted endowment funds. The statement is effective for all fiscal years ending after December 15, 2008. A key component of ASC 958-205 is required for expanded disclosure for all endowment funds (Note 11).

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

(ii) *Accounting for Uncertainty in Income Taxes*

FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" ("FIN 48"), was issued in July 2006 and was effective for fiscal years beginning after December 15, 2006. Under FIN 48, an organization must recognize the tax benefit associated with tax positions taken for tax return purposes when it is more likely than not the position will be sustained upon examination by a taxing authority.

In February 2008 the FASB issued Staff Position No. 48-2, which defers the effective date of FIN 48 for certain nonpublic enterprises as defined in SFAS No. 109, "Accounting for Income Taxes", until fiscal years beginning after December 15, 2008 and subsequently issued Staff Position No. 48-3 in December 2008. Under SFAS No. 109, a nonpublic enterprise is defined as "an enterprise other than one (a) whose debt or equity securities are traded in a public market, including those traded on a stock exchange or in the over-the-counter market, (b) that is a conduit bond obligor for conduit debt securities that are traded in a public market, or (c) whose financial statements are filed with a regulatory agency in preparation for the sale of any class of securities". As of September 30, 2009, the Society met the definition of a nonpublic enterprise as defined under SFAS No. 109 and has elected to defer the adoption of FIN 48 until fiscal year 2010. As a result, the accounting policy for evaluating uncertain tax positions continues to be based on SFAS No. 5, "Accounting for Contingencies".

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

On September 3, 2009, the FASB issued Accounting Standards Update ("ASU") No. 2009-06, "Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities". At this time, management is assessing the impact, if any, of this ASU on the Society's consolidated financial statements.

### 3. Investments, at Fair Value

The Society's cost and fair value of investments are summarized as follows:

*September 30, 2009*

|                         | Fair value       | Cost             |
|-------------------------|------------------|------------------|
| Certificates of deposit | \$801,611        | \$792,000        |
| Mutual funds            | 5,368            | 5,906            |
| <b>Total</b>            | <b>\$806,979</b> | <b>\$797,906</b> |

The following table presents the level within the fair value hierarchy at which the Society's financial assets and financial liabilities are measured on a recurring basis at September 30, 2009:

| Description             | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant other unobservable inputs (Level 3) | Balance at September 30, 2009 |
|-------------------------|--|---|---|-------------------------------|
| Investments:            |  |   |   |                               |
| Certificates of deposit | \$801,611  | \$ -  | \$-   | \$801,611                     |
| Mutual funds            | -  | 5,368   | -   | 5,368                         |
|                         | <b>\$801,611</b>   | <b>\$5,368</b>                                | <b>\$-</b>                                      | <b>\$806,979</b>              |

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

- 4. Pledges Receivable** Pledges receivable are recorded at their net present value using the appropriate discount rate in effect at the time the pledge is made and are reported net of an allowance for uncollectable pledges. The breakdown of pledges receivable as of September 30, 2009 is as follows:

|                                      |           |
|--------------------------------------|-----------|
| Pledges due:                         |           |
| Within one year                      | \$ 33,551 |
| One to five years                    | 140,150   |
|                                      | 173,701   |
| Less: Discount to present value      | 7,381     |
| Net unconditional pledges receivable | \$166,320 |

Amortization of the discount is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on the contributions.

- 5. Life Insurance** The Society is the beneficiary of a life insurance policy on a donor. The annual premium expense for this policy is offset by annual increases in the cash surrender value of the policy. The cash surrender value of the policy for the year ended September 30, 2009 was \$110,838.

- 6. Fixed Assets, Net** Fixed assets, net consist of the following:

|   |           |
|---|-----------|
| <i>September 30, 2009</i>                       |           |
| Furniture and equipment                         | \$255,332 |
| Leasehold improvements                          | 30,489    |
| Total   | 285,821   |
| Less: Accumulated depreciation and amortization | 267,744   |
| Fixed assets, net                               | \$ 18,077 |

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

Included in the above amounts are fully depreciated assets still in use amounting to \$210,842. Depreciation and amortization expense for the year ended September 30, 2009 was \$18,110.

### 7. Lease Commitments

In fiscal year 2005, the Society entered into a new ten-year agreement to lease office space for its National Office in New York City which was effective June 1, 2005. The Society was granted a rent credit for the first three months of the lease term. The total credit is being amortized on a straight-line basis over the term of the lease. The monthly rent in connection with the agreement, totaling \$11,200, commenced June 1, 2005 and will increase to \$16,672 per month during the final year of the agreement. Rent expense for the year ended September 30, 2009 totaled \$161,736. The minimum future annual lease payments in connection with the agreement are as follows:

| <i>Year ending September 30,</i> |             |
|----------------------------------|-------------|
| 2010                             | \$ 163,827  |
| 2011                             | 167,923     |
| 2012                             | 179,588     |
| 2013                             | 189,411     |
| 2014                             | 194,146     |
| Thereafter                       | 148,412     |
| Total                            | \$1,043,307 |

In addition, the Society leases space for its Chapters at various locations on an annual basis. Rent expense for those locations for the year ended September 30, 2009 totaled \$77,548.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

- 8. Related Party Transactions** Subsequent to November 2007 through September 2008, the private foundation made contributions to the Society in lieu of any agreement of \$900,000. During November 2008, the Society entered into another matching agreement with the private foundation whereby the foundation will match 100% of the cash contributions raised during the fiscal year ending September 30, 2009 in excess of \$6 million, up to a maximum of \$1.5 million.
- 9. Net Assets Released from Restrictions** Net assets released from restrictions by incurring expenses satisfying the restricted purpose or by occurrence of other events specified by donors as of September 30, 2009 totaled \$1,186,383 and \$39,898 for temporarily restricted net assets and permanently restricted net assets, respectively. Released net assets were used primarily to fund research and education.
- 10. Permanently Restricted Net Assets** The Society received a permanently restricted grant from a donor for \$484,556 in December 2002. As per the agreement, the Society is allowed to use 5% of the original grant and any interest earned each year to fund family services. The permanently restricted net assets balance at September 30, 2009 was \$552,200, which consists of two permanently restricted grants.
- 11. Endowment Net Asset Classification** Interpretation of relevant law - the spending of endowment funds by a not-for-profit corporation in the State of New York is currently governed by the Uniform Management of Institutional Funds Act ("UMIFA"), as enacted in 1978 in the New York Not-For-Profit Corporation Law. The Society has interpreted UMIFA as requiring the preservation of the historical dollar value, or principal, of an endowment fund unless the donor provides otherwise by specifying in their written gift instruments that the not-for-profit corporation's spending-rate policy be applied to the endowment funds.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

Investment and spending policies - the Society has adopted investment and spending policies for endowment assets that attempt to provide a stream of returns that would be utilized to fund various programs while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Society must hold in perpetuity, and as directed by the donors, and those assets that are Board designated, as approved by the Board of Directors of the Society. The endowment funds are invested in vehicles such as money market funds, mutual funds, government and equity securities, as well as certificates of deposit.

The Society considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- the duration and preservation of the funds;
- the purposes of the Society and the donor-restricted endowment funds;
- general economic conditions;
- the possible effect of inflation and deflation;
- the expected total return from income and the appreciation/depreciation of investments;
- other resources of the Society; and
- the investment policy of the Society.

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

The following table represents the endowment net asset composition by type of fund as of September 30, 2009:

|                          | Donor-<br>restricted<br>endowment<br>funds | Board-<br>designated<br>endowment<br>funds | Total<br>endowments |
|--------------------------|--|--|---------------------|
| Permanently restricted   | \$552,200                                  | \$ -                                       | \$ 552,200          |
| Temporarily restricted   | 377,902                                    | -  | 377,902             |
| Unrestricted             | -  | 443,603                                    | 443,603             |
| Total endowment<br>funds | \$930,102                                  | \$443,603                                  | \$1,373,705         |

The following table represents the reconciliation of changes in endowment net assets for the year ended September 30, 2009:

|  | Donor-<br>restricted<br>endowment<br>funds | Board-<br>designated<br>endowment<br>funds | Total<br>endowments |
|--|--|--|---------------------|
| Endowment net assets,<br>beginning of year | \$1,115,221                                | \$443,603                                  | \$1,558,824         |
| Investment return:                         |  |  |                     |
| Investment income                          | 31,633                                     | -  | 31,633              |
| Net appreciation                           | 15,192                                     | -  | 15,192              |
| Total investment<br>return                 | 46,825                                     | -  | 46,825              |
| Transfers to (from)<br>endowment:          |  |  |                     |
| Net transfers into<br>endowment            | 102,045                                    | -  | 102,045             |
| Net transfers from<br>endowment            | (333,989)                                  | -  | (333,989)           |
| Net transfers from<br>endowment            | (231,944)                                  | -  | (231,944)           |
| Endowment net assets,<br>end of year       | \$ 930,102                                 | \$443,603                                  | \$1,373,705         |

# Huntington's Disease Society of America, Inc. and Affiliates

## Notes to Consolidated Financial Statements

- 12. Donated Services** During fiscal year 2009, the Society received donated services such as media support in the area of education and awareness through public service announcements and electronic media campaigns. These services were an integral part of the activities of the Society and would have had to be purchased by the Society if they had not been donated. The services were recorded at the fair market value based on what it would have cost the Society to purchase them independently and have been reflected as support and expenses in the consolidated statement of activities. The fair value of donated services for the year ended September 30, 2009 was \$90,069.
- 13. Pension Plan** The Society maintains a 403(b) defined contribution pension plan for all eligible employees. The Society contributes a 5% match of an eligible employee's salary to the pension plan. The Society's contribution for the year ended September 30, 2009 totaled \$51,033.
- 14. Subsequent Events** The Society's management has performed subsequent events procedures through March 31, 2010 which is the date the consolidated financial statements were available to be issued and there were no subsequent events requiring adjustment to the consolidated financial statements or disclosures as stated herein.

## **Independent Auditors' Report on Supplemental Material**

Our audit was made for the purpose of forming an opinion on the basic consolidated financial statements taken as a whole. The supplemental material is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic consolidated financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic consolidated financial statements taken as a whole.

*BDO Seidman, LLP*

Certified Public Accountants

New York, New York

March 31, 2010

# Huntington's Disease Society of America, Inc. and Affiliates

## Consolidating Statement of Financial Position

September 30, 2009

|  | National<br>Organization | Group<br>Exemption | HDSA<br>Research<br>Initiatives | HDSA Care<br>Centers<br>Initiatives | Total              |
|--|--------------------------|--------------------|---------------------------------|-------------------------------------|--------------------|
| <b>Assets</b>                          |                          |                    |                                 |                                     |                    |
| Cash and cash equivalents              | \$1,392,659              | \$ 861,044         | \$ 746,663                      | \$1,910                             | <b>\$3,002,276</b> |
| Investments, at fair value             | -                        | -                  | 806,979                         | -                                   | <b>806,979</b>     |
| Contributions receivable               | 940,465                  | 132,417            | -                               | -                                   | <b>1,072,882</b>   |
| Pledges receivable, net                | 161,720                  | 4,600              | -                               | -                                   | <b>166,320</b>     |
| Prepaid expenses and deposits          | 148,199                  | -                  | -                               | -                                   | <b>148,199</b>     |
| Cash surrender value of life insurance | 110,838                  | -                  | -                               | -                                   | <b>110,838</b>     |
| Fixed assets, net                      | 12,875                   | 5,202              | -                               | -                                   | <b>18,077</b>      |
|  | <b>\$2,766,756</b>       | <b>\$1,003,263</b> | <b>\$1,553,642</b>              | <b>\$1,910</b>                      | <b>\$5,325,571</b> |
| <b>Liabilities and Net Assets</b>      |                          |                    |                                 |                                     |                    |
| <b>Liabilities:</b>                    |                          |                    |                                 |                                     |                    |
| Accounts payable and accrued expenses  | \$ 544,949               | \$ -               | \$ -                            | \$ -                                | <b>\$ 544,949</b>  |
| Accrued compensation                   | 274,789                  | -                  | -                               | -                                   | <b>274,789</b>     |
| Research grants payable                | 1,890,000                | -                  | 617,500                         | -                                   | <b>2,507,500</b>   |
| Accrued lease commitment               | 113,314                  | -                  | -                               | -                                   | <b>113,314</b>     |
| Deferred revenue                       | 81,927                   | 33,551             | -                               | -                                   | <b>115,478</b>     |
|  | 2,904,979                | 33,551             | 617,500                         | -                                   | <b>3,556,030</b>   |
| <b>Net assets:</b>                     |                          |                    |                                 |                                     |                    |
| Unrestricted                           | (138,223)                | 969,712            | (792,397)                       | 1,910                               | <b>41,002</b>      |
| Unrestricted - Board designated        | -                        | -                  | 443,603                         | -                                   | <b>443,603</b>     |
| Temporarily restricted                 | -                        | -                  | 732,736                         | -                                   | <b>732,736</b>     |
| Permanently restricted                 | -                        | -                  | 552,200                         | -                                   | <b>552,200</b>     |
| <b>Total net assets</b>                | <b>(138,223)</b>         | <b>969,712</b>     | <b>936,142</b>                  | <b>1,910</b>                        | <b>1,769,541</b>   |
|  | <b>\$2,766,756</b>       | <b>\$1,003,263</b> | <b>\$1,553,642</b>              | <b>\$1,910</b>                      | <b>\$5,325,571</b> |

# Huntington's Disease Society of America, Inc. and Affiliates

## Consolidating Statement of Activities

Year ended September 30, 2009

|  | National<br>Organization | Group<br>Exemption | HDSA<br>Research<br>Initiatives | HDSA Care<br>Centers<br>Initiatives | Eliminations       | Total               |
|--|--------------------------|--------------------|---------------------------------|-------------------------------------|--------------------|---------------------|
| <b>Public support and revenue:</b>                                   |                          |                    |                                 |                                     |                    |                     |
| Public support   | \$ 5,331,398             | \$ 1,211,671       | \$ -                            | \$ -                                | \$ -               | \$ 6,543,069        |
| Indirect support   | -                        | -                  | 2,535,216                       | 769                                 | (2,535,985)        | -                   |
| <b>Total public support and revenue</b>                              | <b>5,331,398</b>         | <b>1,211,671</b>   | <b>2,535,216</b>                | <b>769</b>                          | <b>(2,535,985)</b> | <b>6,543,069</b>    |
| <b>Expenses:</b>   |                          |                    |                                 |                                     |                    |                     |
| Program services:  |                          |                    |                                 |                                     |                    |                     |
| Grants to related organizations                                      | 1,180,937                | 1,355,048          | -                               | -                                   | (2,535,985)        | -                   |
| Research   | 2,014,699                | -                  | 2,983                           | -                                   | -                  | 2,017,682           |
| Family services  | 1,815,238                | 298,275            | 11,258                          | -                                   | -                  | 2,124,771           |
| Education  | 821,952                  | 10,319             | 2,983                           | -                                   | -                  | 835,254             |
| Chapter development  | 1,647,787                | -                  | 2,983                           | -                                   | -                  | 1,650,770           |
| <b>Total program services</b>  | <b>7,480,613</b>         | <b>1,663,642</b>   | <b>20,207</b>                   | <b>-</b>                            | <b>(2,535,985)</b> | <b>6,628,477</b>    |
| Supporting services:   |                          |                    |                                 |                                     |                    |                     |
| Management and general   | 219,244                  | 725,616            | 3,513                           | -                                   | -                  | 948,373             |
| Fundraising  | 781,277                  | 343,871            | 16,290                          | -                                   | -                  | 1,141,438           |
| <b>Total supporting services</b>                                     | <b>1,000,521</b>         | <b>1,069,487</b>   | <b>19,803</b>                   | <b>-</b>                            | <b>-</b>           | <b>2,089,811</b>    |
| <b>Total expenses</b>  | <b>8,481,134</b>         | <b>2,733,129</b>   | <b>40,010</b>                   | <b>-</b>                            | <b>(2,535,985)</b> | <b>8,718,288</b>    |
| <b>Net income (loss) from operations before nonoperating revenue</b> | <b>(3,149,736)</b>       | <b>(1,521,458)</b> | <b>2,495,206</b>                | <b>769</b>                          | <b>-</b>           | <b>(2,175,219)</b>  |
| <b>Nonoperating revenue:</b>   |                          |                    |                                 |                                     |                    |                     |
| Special events:  |                          |                    |                                 |                                     |                    |                     |
| Gross receipts   | 2,078,194                | 1,982,935          | -                               | -                                   | -                  | 4,061,129           |
| Less: Direct costs   | (1,191,454)              | (451,346)          | -                               | -                                   | -                  | (1,642,800)         |
| <b>Net revenue from special events</b>                               | <b>886,740</b>           | <b>1,531,589</b>   | <b>-</b>                        | <b>-</b>                            | <b>-</b>           | <b>2,418,329</b>    |
| <b>Change in net assets</b>  | <b>(2,262,996)</b>       | <b>10,131</b>      | <b>2,495,206</b>                | <b>769</b>                          | <b>-</b>           | <b>243,110</b>      |
| <b>Net assets, beginning of year</b>                                 | <b>2,124,773</b>         | <b>959,581</b>     | <b>(1,559,064)</b>              | <b>1,141</b>                        | <b>-</b>           | <b>1,526,431</b>    |
| <b>Net assets, end of year</b>                                       | <b>\$ (138,223)</b>      | <b>\$ 969,712</b>  | <b>\$ 936,142</b>               | <b>\$1,910</b>                      | <b>\$ -</b>        | <b>\$ 1,769,541</b> |